Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 81-89

  Liu, An ^a   Chen, Hui ^a   Wei, Weitian ^a   Ye, Sheng ^a   Liao, Wei ^a   Gong, Jianming ^a   Jiang, Zhengcai ^a   Wang, Lian ^a   Lin, Shengzhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Emodin; Pancreatic neoplasms; Transcription factor nuclear factor B

Indexed keywords

CASPASE 3; EMODIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NF-KAPPA B; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79955867755     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1257     Document Type: Article

References (23)

1. Rivera F, López-Tarruella S, Vega-Villegas ME, et al: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335-339, 2009.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Demirezer LO, Kuruüzüm-Uz A, Bergere I, et al: The struc tures of antioxidant and cytotoxic agents from natural source: anthraquinones and tannins from roots of Rumex patientia. Phytochemistry 58: 1213-1217, 2001. (Pubitemid 34019490)
4. Huang Q, Lu G, Shen HM, et al: Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27: 609-630, 2007.
5. Li J, Liu P, Mao H, et al: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
6. Ko JC, Su YJ, Lin ST, et al: Suppression of ERCCl and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79: 655-664, 2010.
7. Chun-Guang W, Jun-Qing Y, Bei-Zhong L, et al: Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol 627: 33-41, 2010.
8. Chen H, Wei WT, Guo YF, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
9. Lee MA, Park GS, Lee HJ, et al: Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 5: 127, 2005.
10. Yang LQ, Fang DC, Wang RQ, et al: Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10: 2-25, 2004.
11. Liu X, Gao R, Dong Y, et al: Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition. BMC Cancer 10: 418, 2010.
12. Cheung CH, Sun X, Kanwar JR, et al: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int 10: 36, 2010.
13. Kunnumakkara AB, Guha S, Krishnan S, et al: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007. (Pubitemid 46762173)
14. Böhle AS and Kalthoff H: Molecular mechanisms of tumor metastasis and angiogenesis. Langenbecks Arch Surg 384: 133-140, 1999. (Pubitemid 29227304)
15. Montgomery AM, Mueller BM, Reisfeld RA, et al: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54: 5467-5473, 1994. (Pubitemid 24336042)
16. Ho LL, Chen WJ, Lin-Shiau SY, et al: Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. Eur J Pharmacol 453: 149-158, 2002.
17. Alhasan SA, Aranha O and Sarkar FH: Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res 7: 4174-4181, 2001. (Pubitemid 34044643)
18. Abiru S, Nakao K, Ichikawa T, et al: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35: 1117-1124, 2002. (Pubitemid 34454008)
19. Liptay S, Weber CK, Ludwig L, et al: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746, 2003. (Pubitemid 36706095)
20. Banerjee S, Kaseb AO, Wang Z, et al: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69: 5575-5583, 2009.
21. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
22. Adachi S, Kokura S, Okayama T, et al: Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 25: 210-219, 2009.
23. Kuo TC, Yang JS, Lin MW, et al: Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330: 736-744, 2009.